Boston Scientific Corporation vs Vanguard Information Technology Index Fund ETF — how do they compare? Boston Scientific Corporation trades at $51.48 (market cap $74.19B), while Vanguard Information Technology Index Fund ETF trades at $121.87. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | VGT | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | — |
52-Week High | $108.14 | $125.77 |
52-Week Low | $42.63 | $83.59 |
Enterprise Value | $86.27B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
VGT trades at $121.85, up 1.33% with strong bullish momentum from moving averages. The ETF benefits from institutional accumulation and positive AI infrastructure exposure. Technical indicators show RSI_6 at 82.74 suggesting overbought conditions while ADX signals strong trend strength. Recent news highlights institutional buying sprees and Microsoft's earnings boost to tech ETFs.
Outlook remains positive given institutional confidence and AI-driven growth, though concentration risk and overbought technicals warrant caution. The pure-tech focus has outperformed broader tech ETFs historically, but semiconductor volatility presents near-term headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →